JP2011521969A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521969A5
JP2011521969A5 JP2011511843A JP2011511843A JP2011521969A5 JP 2011521969 A5 JP2011521969 A5 JP 2011521969A5 JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011521969 A5 JP2011521969 A5 JP 2011521969A5
Authority
JP
Japan
Prior art keywords
composition
kinase
inhibitor
activin receptor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011511843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045607 external-priority patent/WO2009146408A1/en
Publication of JP2011521969A publication Critical patent/JP2011521969A/ja
Publication of JP2011521969A5 publication Critical patent/JP2011521969A5/ja
Pending legal-status Critical Current

Links

JP2011511843A 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 Pending JP2011521969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5746108P 2008-05-30 2008-05-30
US61/057,461 2008-05-30
PCT/US2009/045607 WO2009146408A1 (en) 2008-05-30 2009-05-29 Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions

Publications (2)

Publication Number Publication Date
JP2011521969A JP2011521969A (ja) 2011-07-28
JP2011521969A5 true JP2011521969A5 (enExample) 2011-09-08

Family

ID=41377599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511843A Pending JP2011521969A (ja) 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件

Country Status (5)

Country Link
US (1) US20100087486A1 (enExample)
EP (1) EP2285380A4 (enExample)
JP (1) JP2011521969A (enExample)
CN (1) CN102083439A (enExample)
WO (1) WO2009146408A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267731A1 (en) * 2009-04-17 2010-10-21 Summa Health Systems, LLC Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
CN103167875A (zh) * 2010-08-17 2013-06-19 阿勒根公司 用于治疗角膜浑浊的ep2或ep4激动剂
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
JP6461787B2 (ja) 2013-04-12 2019-01-30 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
WO2014185358A1 (ja) 2013-05-14 2014-11-20 国立大学法人京都大学 効率的な心筋細胞の誘導方法
MX386503B (es) 2013-07-30 2025-03-19 Kyoto Prefectural Public Univ Corp Medicamentos terapeuticos de matriz extracelular endotelial corneal.
JP6378183B2 (ja) 2013-08-07 2018-08-22 国立大学法人京都大学 膵ホルモン産生細胞の製造法
CN121136933A (zh) 2013-09-05 2025-12-16 国立大学法人京都大学 由多能干细胞制造产多巴胺神经前体细胞的方法、产多巴胺神经前体细胞、帕金森病治疗剂和试剂盒
CA2927898C (en) * 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
CN106536718B (zh) 2014-05-21 2021-04-27 国立大学法人京都大学 胰芽细胞的制造方法及含有胰芽细胞的胰疾病治疗剂
JP7072507B2 (ja) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
EP3447130A4 (en) 2016-04-22 2019-11-13 Kyoto University METHOD FOR PRODUCING DOPAMINE-PROPERING NEURAL PRESERVATOR CELLS
CN106282092A (zh) * 2016-09-07 2017-01-04 山东省眼科研究所 一种角膜内皮分离和扩增培养液
WO2018216743A1 (ja) 2017-05-25 2018-11-29 国立大学法人京都大学 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法
CA3096870A1 (en) 2018-02-19 2019-08-22 Sumitomo Dainippon Pharma Co., Ltd. Cell aggregate, mixture of cell aggregates, and method for preparing same
WO2020022261A1 (ja) 2018-07-23 2020-01-30 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
WO2020230832A1 (ja) 2019-05-15 2020-11-19 味の素株式会社 神経堤細胞または角膜上皮細胞の純化方法
JPWO2020235319A1 (enExample) 2019-05-20 2020-11-26
US12533383B2 (en) 2019-09-06 2026-01-27 Keio University Method for producing cell aggregate including glial progenitor cells
US12577536B2 (en) 2019-10-01 2026-03-17 Kyoto University Method for isolating ureteric bud tip cells
WO2021187601A1 (ja) 2020-03-19 2021-09-23 国立大学法人京都大学 心筋細胞の精製方法
EP4123016A4 (en) 2020-03-19 2024-06-19 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
US20230256024A1 (en) 2020-07-13 2023-08-17 Kyoto University Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
US20240010989A1 (en) 2021-01-08 2024-01-11 Kyoto University Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids
WO2022259721A1 (ja) 2021-06-10 2022-12-15 味の素株式会社 間葉系幹細胞の製造方法
AU2022294563A1 (en) 2021-06-17 2024-01-18 Kyoto University Method for producing cerebral cortical cell preparation derived from human pluripotent stem cells
WO2023286852A1 (ja) 2021-07-15 2023-01-19 株式会社セルファイバ 構造体及びその用途
EP4386083A4 (en) 2021-08-11 2025-11-12 Univ Kyoto METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS AND METHOD FOR PRODUCING RENIIN-PRODUCING CELLS
US20250163385A1 (en) 2022-02-01 2025-05-22 Kyoto University Method for producing lung mesenchymal cells and lung mesenchymal cells
JPWO2023153464A1 (enExample) 2022-02-09 2023-08-17
EP4530344A1 (en) 2022-05-23 2025-04-02 Kyoto University Production method for renal collecting duct cells and pelvic epithelial cells
EP4596675A4 (en) 2022-09-26 2026-03-11 Univ Kyoto PROCESS FOR THE PRODUCTION OF PANCREATIC ENDODERMAL CELLS

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
EP0670732A1 (en) * 1993-09-29 1995-09-13 Alcon Laboratories, Inc. Compositions containing growth factors and antimetabolites
CA2149657A1 (en) * 1993-09-29 1995-04-06 Billie M. York Compositions containing growth factors and antiplastic agents
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US7148250B2 (en) * 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003300099A1 (en) * 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
DE602004014347D1 (de) * 2003-03-12 2008-07-24 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
ES2389258T3 (es) * 2003-06-17 2012-10-24 Millennium Pharmaceuticals, Inc. Composiciones y métodos para inhibir TGF-s
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20060234911A1 (en) * 2005-03-24 2006-10-19 Hoffmann F M Method of reversing epithelial mesenchymal transition
CN101330914A (zh) * 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
CA2657227A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
US7524640B2 (en) * 2006-08-06 2009-04-28 Children's Medical Center Corporation Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia

Similar Documents

Publication Publication Date Title
JP2009280627A5 (enExample)
DK2729123T3 (en) Cannabinoidreceptorbindende funds and formations and methods
CA2796575C (en) Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
JP2009102342A5 (enExample)
IL260579A (en) Diagnosis, prevention and treatment of joint diseases
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EA202091303A2 (ru) Композиция ингибитора jak для местного применения
WO2007102241A1 (ja) 外用の医薬組成物
JP2014518266A5 (enExample)
CN102821791A (zh) 透皮递送贴剂
RU2013121788A (ru) Ингибиторы репликации вич
HRP20120254T1 (hr) Pripravak za produljenu lokalnu anesteziju koji sadrži saib
CN104379139A (zh) 贴附剂
TW201141524A (en) Stabilized ophthalmic galactomannan formulations
TW201004617A (en) Anti-inflammatory analgesic agent for external use
CA2717948A1 (en) 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
ES2457519T3 (es) Pasta a base de agua que contiene diclofenaco sódico
WO2009109654A3 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
CN105997951A (zh) 一种包含卡巴拉汀的透皮给药系统及制备方法
WO2014110353A8 (en) Notch ligand bound biocompatible substrates and their use in bone formation
CA2785242A1 (en) Carrier composition
CA2785851A1 (en) Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
JP2009532373A5 (enExample)
ITMI20071724A1 (it) Formulazioni topiche antivirali in forma di gel bioadesivo
WO2019089523A1 (en) Hydrophobic acid addition salts and pharmaceutical formulations thereof